Q4 2017 13F Holders as of 31 Dec 2017
-
Type / Class
-
Equity / Common Stock, $0.001 par value
-
Shares outstanding
-
99,963,154
-
Total 13F shares
-
93,842,806
-
Share change
-
-2,009,549
-
Total reported value
-
$7,281,125,612
-
Put/Call ratio
-
122%
-
Price per share
-
$77.59
-
Number of holders
-
260
-
Value change
-
-$128,562,595
-
Number of buys
-
136
-
Number of sells
-
113
Institutional Holders of NEUROCRINE BIOSCIENCES INC - Common Stock, $0.001 par value (NBIX) as of Q4 2017
As of 31 Dec 2017,
NEUROCRINE BIOSCIENCES INC - Common Stock, $0.001 par value (NBIX) was held by
260 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
93,842,806 shares.
The largest 10 holders included
FMR LLC, Vanguard Group Inc, PRICE T ROWE ASSOCIATES INC /MD/, JANUS HENDERSON GROUP PLC, PERCEPTIVE ADVISORS LLC, BlackRock Inc., BB BIOTECH AG, WELLINGTON MANAGEMENT GROUP LLP, FRANKLIN RESOURCES INC, and Invesco Ltd..
This page lists
260
institutional shareholders reporting positions in this security
for the Q4 2017 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.